Merck enhances ophthalmology portfolio with EyeBio acquisition
Pharmaceutical Business Review
JULY 15, 2024
This asset has potential applications in diabetic macular oedema (DME) and neovascular age-related macular degeneration (NVAMD). The acquisition includes EyeBio’s lead asset Restoret (EYE-103), a tetravalent, tri-specific antibody that targets the Wingless-related integration site (Wnt) signalling pathway.
Let's personalize your content